Assessing Severity. Management of Stable COPD. General Approach. Short Acting Bronchodilators. Staging System (GOLD)
|
|
|
- Winifred Thomas
- 5 years ago
- Views:
Transcription
1 William P. Saliski Jr. DO Montgomery Pulmonary Consultants Management of Stable COPD Pharmacotherapy Oxygen Smoking Cessation Vaccinations Rehabilitation Surgery Future Discussions Assessing Severity Staging System (GOLD) Defines disease severity by FEV1 and ratio FEV1/FVC Used as a guide to manage patient therapy General Approach Pharmacotherapy prevent/decrease symptoms reduce exacerbations improve health status improve exercise capacity Short Acting Bronchodilators Beta agonists albuterol, levabuteral, pirbuterol (SABA) Anticholinergics ipratropium bromide
2 Short Acting Bronchodilators Names Albuterol Sulfate Levalbuterol Porbuterol Provental HFA Ventolin HFA Proair HFA Xopenex Maxair Ipatroprium Bromide Atrovent Beta Agonist Therapy Dosing : 2 Puffs as needed Side Effects : tremor, reflex tachycardia hypokalemia ( extreme use ) Combu Med Combivent Anticholinergic Therapy Dosing 2 puffs 4x/daily 18 meq/puff 200 puffs/canister Side Effects dry mouth, constipation? Cardiovascular side effects Combination Therapy (Combivent) Dosing 2 puffs 4x/daily Combination therapy increased FEV1 more than either agent alone Long Acting Bronchodilators (LABA) Salmeterol Serevent Formoterol Foradil Arfomoterol Brovena (nebulizer use) Tiotropium Spiriva Therapy in Gold II IV Beta Agonists (LABA) Dosing both are dry powder used 2x/daily Side Effects same as short acting agents increase risk of death (Smart trial)
3 Dosing dry powder 1x/daily Anticholinergics (Long Acting) Comparison Shopping Foradil> Serevent Spiriva>Foradil>Serevent Side Effects dry mouth, headache constipation, glaucoma (worsening) Foradil has rapid onset, lasts longer Spiriva affords better bronchodilation and better side effect profile Bronchodilators Plus Inhaled Glucocorticosteroids (ICS) COPD characterized by airway and systemic inflammation Numerous ICS on the market No real difference in products ICS should not be used as sole therapy Bronchodilator Plus ICS Advair Discus/Advair HFA (Fluticasone/Salmeterol)250 meq/50 mcg 2x/daily Symbicort 160/4.5 (Budesonide/Formeterol)2 puffs 2x/daily Side Effects (ICS) oral candidiasis, pneumonia, adrenal suppression
4 Triple Inhaler Therapy Stage III IV Gold LABA/ICS and tiotroprium bromide Decrease mortality, exacerbations, and hospitalizations Theophylline Mechanism of action controversial Offers moderate bronchodilation Long acting extended release preps Narrow LD 50 Metabolized in liver Keep serum level 8 to 12 mcg/ml Rarely Used Medications Systemic Glucocorticoids Mucoactive Agents Chronic Antibiotic Therapy Supplemental Therapy Oxygen Secretion Clearance Smoking Cessation Vaccinations Rehabilitation Nutrition Oxygen Therapy Long term oxygen therapy (LTOT) increases survival and improves quality of life Minimal adverse effects (humidify!) Close government regulation 2 billion dollars per year (Medicare)
5 LTOT Indications PaO2 55 mm Hg or SaO2 88 % Cor Pulmonale PaO2 59 mm Hg/SaO2 89 % (Hct > 55 %, EKG p pulmonale, CHF Desaturation with above numbers w/ exercise or at sleep Prescribing Oxygen Obtain baseline ABG (does O2 Sat correlate?) (is patient hypercarbic?) Keep PaO2 60 to 65 mm Hg Keep SaO2 92% Usually order 2L NC (continuous, exercise, sleep?) Equipment Selection Keep your patient mobile Select lightest, most portable Think liquid O2 Oxygen conserving device Secretion Clearance Postural drainage Flutter valve therapy Hydration? Oxygen concentrator (bedroom) Vaccinations Pneumococcal/polysaccharide vaccine COPD 65 yrs old COPD 65 yrs old w/ FEV1< 40% predicted Active tobacco use Give initial vaccine and 5 year booster Does not reduce mortality Vaccinations Influenza vaccination given to all patients with COPD Decrease risk of influenza significantly DOES NOT CAUSE THE FLU! Timing?
6 Clinician advice Smoking Cessation Nicotine replacement therapy Buproprion (Zyban) 150 mg Varenicline (Chantix) 1 mg Combination therapy best outcome Rehabilitation Low cost effective program Optimizes physical and social functioning Reduces hospitalization, LOS,? Mortality Medically supervised Rehabilitation Baptist Medical Center South Anita Jones Covered by Major Medical Insurances Nutrition 30% of patients with severe COPD are protein calorie malnourished Increase mortality, decrease muscle function, decrease immunity Try high caloric dietary supplements Magestrol acetate (Megace)
7
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
A Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
Prescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
A Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
A Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
Improving Outcomes in COPD
Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea
Presented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
Chronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
Provider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center
Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking
COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
Exacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
COPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
Foundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
UPMC HEALTH PLAN COPD CLINICAL PRACTICE GUIDELINE
Relevance to Population: COPD affects 12 million people in the United States, making it the 4 th leading cause of mortality and the 2 nd leading cause of disability. It is predicted that these statistics
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease CareOregon Pharmacy Abridged sample of presentation content Home Equipment Pathophysiology Exacerbations Guidelines Lifestyle Modification Medication Management Sample
Balanced information for better care. Helping patients with COPD breathe easier
Balanced information for better care Helping patients with COPD breathe easier COPD is the third-leading cause of death in the U.S., following cancer and heart disease 1 FIGURE 1. Women now have a higher
COPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
COPD. Stan Kellar, MD. Physiology 11/4/2014. Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine
Stan Kellar, MD Chief of Clinical Affairs, BH NLR Pulmonary Medicine Sleep Medicine COPD Physiology The lungs are filters Filter in oxygen Filter out carbon dioxide (Vascular filter, not part of this discussion)
II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
Women Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
Salford COPD Treatment Pathway
Salford COPD Treatment Pathway Development led by Helen Pyne with Salford Asthma and Respiratory Team (SART) Department Respiratory Medicine Salford Royal NHS Foundation Trust Hope Hospital, Stott Lane,
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
COPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
SABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
MANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
COPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline
Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They
COPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
What is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
Inhalation devices, proper technique and cleaning
Preventing Your Symptoms and Taking Your Medications Inhalation devices, proper technique and cleaning Knowing how to use your medications properly is important because inhaled drugs are meant to get directly
COPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.
Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate
PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet
PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet What is COPD? COPD is a general term, which includes the conditions chronic asthma, chronic bronchitis and emphysema. It is due
Algorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
Nancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
Women Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
COPD. Definitionn. make. when (bronchioles) in. the lungs. Wheezing Chest tightness. your lungs. greenish. Lack of energy
COPD Definitionn Emphysema and chronic bronchitis are the two most common conditions thatt make up COPD. Chronic bronchitis is an inflammation of the lining of your bronchial tubes, which carry air to
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
Chronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
Common Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
AECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
COPD. Understanding. An educational health series from National Jewish Health IN THIS ISSUE. What is COPD? 2. How is COPD Managed?
Understanding COPD The Mount Sinai National Jewish Health Respiratory Institute was formed by the nation s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic
STRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
Medications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
Disclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
Fighting for Air, In Emphysema
Fighting for Air, The Mechanism of Shortness of Breath In Emphysema Albert A. Rizzo, MD FCCP FACP Speaker, Nationwide Assembly of the American Lung Association & Section Chief Pulmonary/Critical Care Medicine
Bronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)
Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from
Drug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
Respiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
Algorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
Chronic Obstructive Pulmonary Disease
COPD Guideline Team Team Leader Davoren A Chick, MD General Medicine Team Members Paul J Grant, MD General Medicine Meilan K Han, MD, MS Pulmonary Medicine R Van Harrison, PhD Medical Education Elisa B
Chronic Obstructive Pulmonary Disease
Scope of Problem Chronic Obstructive Pulmonary Disease Marianne J. Davies, RN, MSN, APRN Yale University School of Medicine Yale Comprehensive Cancer Center Nevada Cancer Institute 2005 Hospitalizations
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 May 2011 Examination of the file for the proprietary medicinal product included for a period of 5 years by the
Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More
Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More Char Raley, RRT Brandon Johnson, PharmD, BCPS Pulmonary and Critical Care Symposium June 12 th, 2015 We have had no
COPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
COPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
Diagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
Wirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
Asthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
COPD. Diseases and Conditions
Diseases and Conditions COPD By Mayo Clinic Staff Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) Definition Etiology Epidemiology Pathophysiology Clinical i l Presentation ti Diagnosis Prevention Treatment COPD: Outline COPD: Definition Chronic airflow
AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN
Drugs that Affect the Respiratory System BROOKE BENTLEY, PHD, APRN Goals of Therapy Asthma Prevent symptoms COPD Reduce COPD symptoms Decrease use of SABAs Maintain normal pulm function & prevent loss
Integrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
Debating the use of inhaled corticosteroids in the treatment of COPD. COPD Epidemiology. A quick patient case. Risk Factors for COPD 1,2
Debating the use of inhaled corticosteroids in the treatment of COPD Suzanne G. Bollmeier Pharm.D., BCPS, AE-C Associate Professor, St. Louis College of Pharmacy ACPE Guidelines on Non- Commercialism o
Asthma COPD Update 2018
Asthma COPD Update 2018 Roger Hefflinger, Pharm.D. Clinical Associate Professor ISU COP Clinical Teaching Pharmacist Family Medicine Residency of Idaho In support of improving patient care, Idaho State
Address Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
MDI Bonanza. Dwayne Griffin, DO
MDI Bonanza Dwayne Griffin, DO Bonanza 3. A MDI costing $200 - $500 per month SISYPHUS MDI Griffin Mountain Evolution of Deliver Systems for COPD in the US 2003 2009 2011 2013 2004 2012 2014 Prescribing
Treatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
History & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
PFT s / 2017 Pulmonary Update. Eric S. Papierniak, DO University of Florida NF/SG VHA
PFT s / 2017 Pulmonary Update Eric S. Papierniak, DO University of Florida NF/SG VHA Outline Overview of pulmonary function testing Uses/indications/limitations Technical aspects Basics of interpretation
NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
HEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 9 PURPOSE To assure that DOP inmates with Pulmonary Diseases are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers and Chronic Disease Nurses are
Better Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
Chronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE
REVISED RESPIRATORY MEDICATION USE QUESTIONNAIRE ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: This form should be completed during the participant s clinic visit. 1) Are you regularly
What You Need to Know about Metered-Dose Inhalers and the HFA Propellant
What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding
COPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
How can I benefit most from my COPD medications?
Fact Sheet: COPD Medications and Delivery Devices How can I benefit most from my COPD medications? COPD medications can improve your symptoms. By taking the right medication at the right time, you can
Proposed Preferred Drug List. Clinical Criteria
Proposed Preferred Drug List with Clinical Criteria Proposal for TennCare February 7, 2008 Page 1 of 87 PDL Decision Process The primary clinical decision that needs to be made is determining if the drugs
Asthma. Definition. Symptoms
Asthma Definition Asthma is a condition in which your airways narrow and swell and produce extra mucus. This can make breathing difficult and trigger coughing, wheezing and shortness of breath. For some
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
Improving Outcomes in COPD. Improving Outcomes in COPD 4/4/2018
Updates 2018 Neil MacIntyre MD Duke University Durham NC. Barnes PJ. N Engl J Med. 2000;343:269-80. 1 COPD spectrum Proximal predominant (large airways) mucus gland hypertrophy (cough/sputum) reduced respiraty
Update on Pulmonary Diseases. Jeffrey Lessar, MD
Update on Pulmonary Diseases Jeffrey Lessar, MD 1 No disclosures to make No conflicts 2 Goals Update on key changes in Pulmonary Therapy 3 Spirometry Spirometry FEV1- forced expiratory Volume in 1 Sec
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
COPD exacerbation. Chiara Maruggi, PGY2
COPD exacerbation Chiara Maruggi, PGY2 Learning objectives At the end of this lecture students will be able to: 1) Critically assess patients for COPD and design a management plan. 2) Develop a step-wise